TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preoperative Vaginal Cleansing With Povidone Iodine and the Risk of Post Cesarean Endometritis
Brief Summary: Preoperative vaginal cleansing with povidone iodine and the risk of post cesarean endometritis.


Options:
A: Arm Label: Iodine-alcohol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Iodine-alcohol | Arm Label: Chlorhexidine-alcohol; Type: EXPERIMENTAL; Interventions: Drug: Chlorhexidine-alcohol | Intervention Type: DRUG; Name: Iodine-alcohol; Assigned to Arm(s): Iodine-alcohol | Intervention Type: DRUG; Name: Chlorhexidine-alcohol; Assigned to Arm(s): Chlorhexidine-alcohol
B: Arm Label: povidone iodine; Type: ACTIVE_COMPARATOR; Interventions: Drug: 10% povidone iodine | Arm Label: no vaginal cleansing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 10% povidone iodine; Assigned to Arm(s): povidone iodine
C: Arm Label: Women going CS without vaginal preparation before surgery; Type: ACTIVE_COMPARATOR; Interventions: Other: No vaginal preparation before CS with Septal soap and septol. | Arm Label: Women going CS with vaginal preparation before surgery; Type: PLACEBO_COMPARATOR; Interventions: Other: vaginal preparation before CS with Septal soap and septol. | Intervention Type: OTHER; Name: vaginal preparation before CS with Septal soap and septol.; Assigned to Arm(s): Women going CS with vaginal preparation before surgery | Intervention Type: OTHER; Name: No vaginal preparation before CS with Septal soap and septol.; Assigned to Arm(s): Women going CS without vaginal preparation before surgery
D: Arm Label: Chlorhexidine Gluconate; Type: EXPERIMENTAL; Interventions: Drug: Chlorhexidine Gluconate | Arm Label: Povidone-Iodine Scrub and Paint; Type: EXPERIMENTAL; Interventions: Drug: Povidone-Iodine Scrub and Paint | Intervention Type: DRUG; Name: Chlorhexidine Gluconate; Assigned to Arm(s): Chlorhexidine Gluconate | Intervention Type: DRUG; Name: Povidone-Iodine Scrub and Paint; Assigned to Arm(s): Povidone-Iodine Scrub and Paint

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Mobile Phone-based Text Message Interventions ('Happy Quit') for Smoking Cessation in China
Brief Summary: The primary objective of this proposed three-year (January 01, 2016 to December 31, 2018) project is to assess whether a program of widely accessed mobile phone-based text message interventions ('Happy Quit') will be effective at helping people in China who smoke, to quit. Based on the efficacy of previous studies in smoking cessation, it is hypothesized that 'Happy Quit' will be an effective, feasible and affordable smoking cessation program in China.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Low Contact | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: QuitTXT Study | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: QuitTXT Study | Intervention Type: BEHAVIORAL; Name: QuitTXT Study; Assigned to Arm(s): 2, 3 | Intervention Type: BEHAVIORAL; Name: Low Contact; Assigned to Arm(s): 1
B: Arm Label: SMS Turkey; Type: EXPERIMENTAL; Interventions: Behavioral: SMS Turkey | Arm Label: Brochure control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SMS Turkey; Assigned to Arm(s): SMS Turkey
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Behavioral: HAR, Behavioral: AWARD, Other: Referral card, Other: A4 leaflet | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Behavioral: LTM, Behavioral: AWARD, Other: Referral card, Other: A4 leaflet | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief advice, Other: 12-page booklet | Intervention Type: BEHAVIORAL; Name: HAR; Assigned to Arm(s): Group A | Intervention Type: BEHAVIORAL; Name: LTM; Assigned to Arm(s): Group B | Intervention Type: BEHAVIORAL; Name: AWARD; Assigned to Arm(s): Group A, Group B | Intervention Type: OTHER; Name: Referral card; Assigned to Arm(s): Group A, Group B | Intervention Type: OTHER; Name: A4 leaflet; Assigned to Arm(s): Group A, Group B | Intervention Type: BEHAVIORAL; Name: Brief advice; Assigned to Arm(s): Group C | Intervention Type: OTHER; Name: 12-page booklet; Assigned to Arm(s): Group C
D: Arm Label: intensive cessation message; Type: EXPERIMENTAL; Interventions: Behavioral: intensive cessation message | Arm Label: No cessation message intervention; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Not intensive cessation message; Type: EXPERIMENTAL; Interventions: Behavioral: Not intensive cessation message | Intervention Type: BEHAVIORAL; Name: intensive cessation message; Assigned to Arm(s): intensive cessation message | Intervention Type: BEHAVIORAL; Name: Not intensive cessation message; Assigned to Arm(s): Not intensive cessation message

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Baduanjin Exercise Prevents Post-Myocardial Infarction Left Ventricular Remodeling (BE-PREMIER Trial)
Brief Summary: Left ventricular (LV) remodeling following myocardial infarction (MI) is an established prognostic factor for adverse cardiovascular events and the leading cause of heart failure. Empirical observations suggests that Baduanjin exercise, an important component of traditional Chinese Qigong, exert potential impacts on cardiopulmonary function. However, the impact of a Baduanjin exercise-based cardiac rehabilitation program for patients recovering from recent MI has yet to be assessed. The aim of this trail is to evaluate whether Baduanjin exercise would prevent the maladaptive progression to adverse LV remodeling in patients following MI.


Options:
A: Intervention Type: BEHAVIORAL; Name: exercise training; Assigned to Arm(s): N/A
B: Arm Label: comprehensive CR; Type: EXPERIMENTAL; Interventions: Behavioral: comprehensive CR | Arm Label: exercise-based CR; Type: ACTIVE_COMPARATOR; Interventions: Other: exercise-based CR | Arm Label: wait list control; Type: OTHER; Interventions: Other: wait list control | Intervention Type: BEHAVIORAL; Name: comprehensive CR; Assigned to Arm(s): comprehensive CR | Intervention Type: OTHER; Name: exercise-based CR; Assigned to Arm(s): exercise-based CR | Intervention Type: OTHER; Name: wait list control; Assigned to Arm(s): wait list control
C: Arm Label: Baduanjin exercise group; Type: EXPERIMENTAL; Interventions: Other: Baduanjin exercise | Arm Label: usual exercise control group; Type: ACTIVE_COMPARATOR; Interventions: Other: aerobic exercise | Intervention Type: OTHER; Name: Baduanjin exercise; Assigned to Arm(s): Baduanjin exercise group | Intervention Type: OTHER; Name: aerobic exercise; Assigned to Arm(s): usual exercise control group
D: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Usual care + letters; Type: EXPERIMENTAL; Interventions: Behavioral: Usual care + letters | Arm Label: Usual care + letters + automated calls; Type: EXPERIMENTAL; Interventions: Behavioral: Usual care + letters + automated calls | Intervention Type: BEHAVIORAL; Name: Usual care + letters; Assigned to Arm(s): Usual care + letters | Intervention Type: BEHAVIORAL; Name: Usual care + letters + automated calls; Assigned to Arm(s): Usual care + letters + automated calls

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Advantages and Disadvantages Between Uncut Roux-en-Y Reconstruction
Brief Summary: The Advantages and Disadvantages Between Uncut Roux-en-Y Reconstruction and Billroth II Reconstruction After Laparoscopy-assisted Distal Gastrectomy for Gastric.


Options:
A: Arm Label: modified BII+Braun; Type: ACTIVE_COMPARATOR; Interventions: Procedure: modified BII+Braun | Arm Label: traditional BII+Braun; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: modified BII+Braun; Assigned to Arm(s): modified BII+Braun
B: Arm Label: Billroth-I; Type: EXPERIMENTAL; Interventions: Procedure: Billroth-I | Arm Label: Roux en Y; Type: EXPERIMENTAL; Interventions: Procedure: Roux en Y | Intervention Type: PROCEDURE; Name: Billroth-I; Assigned to Arm(s): Billroth-I | Intervention Type: PROCEDURE; Name: Roux en Y; Assigned to Arm(s): Roux en Y
C: Arm Label: the group of Roux-en-Y; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Roux-en-Y reconstruction | Arm Label: the group of Uncut Roux-en-Y; Type: EXPERIMENTAL; Interventions: Procedure: Uncut Roux-en-Y reconstruction | Intervention Type: PROCEDURE; Name: Uncut Roux-en-Y reconstruction; Assigned to Arm(s): the group of Uncut Roux-en-Y | Intervention Type: PROCEDURE; Name: Roux-en-Y reconstruction; Assigned to Arm(s): the group of Roux-en-Y
D: Arm Label: Uncut Roux-en-Y Reconstruction; Type: EXPERIMENTAL; Interventions: Procedure: Uncut Roux-en-Y Reconstruction | Arm Label: Billroth II Reconstruction; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Billroth II Reconstruction | Intervention Type: PROCEDURE; Name: Uncut Roux-en-Y Reconstruction; Assigned to Arm(s): Uncut Roux-en-Y Reconstruction | Intervention Type: PROCEDURE; Name: Billroth II Reconstruction; Assigned to Arm(s): Billroth II Reconstruction

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen: The 'Can Do Ramadan' Study
Brief Summary: This study aims to determine if the addition of Canagliflozin (Invokana™) therapy to monotherapy of metformin is more effective at achieving the double composite endpoint of a reduction in HbA1c (≥ 0.3%) and weight loss (≥1kg) 3-4 weeks post-Ramadan. The study will also include patients currently on dual therapy, specifically metformin plus a sulphonylurea, pioglitazone or repaglinide to determine whether switching to metformin plus Canagliflozin (Invokana™) is more effective at achieving the composite endpoint compared to those remaining on previous dual therapy. There are a number of secondary outcomes including weight loss, rates of hypoglycaemia, blood pressure and a number of biochemical endpoints.


Options:
A: Arm Label: Sitagliptin; Type: EXPERIMENTAL; Interventions: Drug: Sitagliptin phosphate, Drug: Metformin | Arm Label: Sulfonylurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Sulfonylurea, Drug: Metformin | Intervention Type: DRUG; Name: Sitagliptin phosphate; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Comparator: Sulfonylurea; Assigned to Arm(s): Sulfonylurea | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Sitagliptin, Sulfonylurea
B: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Device: Telemedicine | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine
C: Arm Label: Canagliflozin + Metformin; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin | Arm Label: Repaglinide + Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Repaglinide | Arm Label: Pioglitazone + Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Arm Label: Gliclazide + Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gliclazide | Arm Label: Glimepiride + Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin + Metformin | Intervention Type: DRUG; Name: Repaglinide; Assigned to Arm(s): Repaglinide + Metformin | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone + Metformin | Intervention Type: DRUG; Name: Gliclazide; Assigned to Arm(s): Gliclazide + Metformin | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride + Metformin
D: Arm Label: Sitagliptin; Type: EXPERIMENTAL; Interventions: Drug: Sitagliptin, Drug: Metformin | Arm Label: Sulfonylurea Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfonylurea, Drug: Metformin | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Sulfonylurea; Assigned to Arm(s): Sulfonylurea Therapy | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Sitagliptin, Sulfonylurea Therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bakri Ballon With or Without Abdominal Traction Stitch in Management of Uterine Bleeding in Cases of Placenta Previa
Brief Summary: The Bakri intrauterine balloon can achieve haemostasis in cases of postpartum haemorrhage, including haemorrhage associated with placenta previa by compressing the lower uterine segment.


Options:
A: Arm Label: Tampostat; Type: EXPERIMENTAL; Interventions: Device: Tampostat | Arm Label: Condom catheter tamponade; Type: ACTIVE_COMPARATOR; Interventions: Device: Condom catheter tamponade | Intervention Type: DEVICE; Name: Tampostat; Assigned to Arm(s): Tampostat | Intervention Type: DEVICE; Name: Condom catheter tamponade; Assigned to Arm(s): Condom catheter tamponade
B: Arm Label: Early Belfort-Dildy balloon device; Type: EXPERIMENTAL; Interventions: Device: Early Belfort-Dildy Balloon | Arm Label: Late Belfort-Dildy balloon device; Type: OTHER; Interventions: Device: Late Belfort-Dildy balloon | Intervention Type: DEVICE; Name: Early Belfort-Dildy Balloon; Assigned to Arm(s): Early Belfort-Dildy balloon device | Intervention Type: DEVICE; Name: Late Belfort-Dildy balloon; Assigned to Arm(s): Late Belfort-Dildy balloon device
C: Arm Label: Bakri Balloon with abdominal traction stitch; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Abdominal traction stitch, Device: Bakri Balloon | Arm Label: Bakri Balloon without abdominal traction stitch; Type: EXPERIMENTAL; Interventions: Device: Bakri Balloon | Intervention Type: PROCEDURE; Name: Abdominal traction stitch; Assigned to Arm(s): Bakri Balloon with abdominal traction stitch | Intervention Type: DEVICE; Name: Bakri Balloon; Assigned to Arm(s): Bakri Balloon with abdominal traction stitch, Bakri Balloon without abdominal traction stitch
D: Arm Label: Room temperature arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Cold Bakri Balloon | Arm Label: Cold arm; Type: EXPERIMENTAL; Interventions: Device: Cold Bakri Balloon | Intervention Type: DEVICE; Name: Cold Bakri Balloon; Assigned to Arm(s): Cold arm, Room temperature arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BI 655066/ABBV-066 (Risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent)
Brief Summary: This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support registration for the treatment of moderate to severe chronic plaque psoriasis in adult patients.


Options:
A: Arm Label: Apremilast; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo, Drug: Placebo-Apremilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Placebo-Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Apremilast, Placebo | Intervention Type: DRUG; Name: Placebo-Apremilast; Assigned to Arm(s): Apremilast, Placebo
B: Arm Label: Adalimumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo for risankizumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Biological: placebo for adalimumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: BIOLOGICAL; Name: placebo for adalimumab; Assigned to Arm(s): Risankizumab (Part A)
C: Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab 45/90 mg, Drug: placebo secukinumab | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg | Intervention Type: DRUG; Name: ustekinumab 45/90 mg; Assigned to Arm(s): Ustekinumab | Intervention Type: DRUG; Name: placebo secukinumab; Assigned to Arm(s): Ustekinumab
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Secukinumab 2 mL form; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 2 mL form | Arm Label: Secukinumab 1 mL form; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab 1 mL form | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Secukinumab 2 mL form; Assigned to Arm(s): Secukinumab 2 mL form | Intervention Type: DRUG; Name: Secukinumab 1 mL form; Assigned to Arm(s): Secukinumab 1 mL form

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Food: An Open-Label, Randomized, Parallel Group Phase 4 Study of the Efficacy and Safety of Patiromer for Oral Suspension With or Without Food for the Treatment of Hyperkalemia (TOURMALINE)
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of patiromer administered once daily (QD) when given with food compared to without food (experimental treatment group) for the treatment of hyperkalemia (high potassium in the blood).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Zirconium silicate (ZS); Type: EXPERIMENTAL; Interventions: Drug: Zirconium silicate (ZS) | Intervention Type: DRUG; Name: Zirconium silicate (ZS); Assigned to Arm(s): Zirconium silicate (ZS) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Group 1 - Dosing Without Food; Type: EXPERIMENTAL; Interventions: Drug: patiromer | Arm Label: Group 2 - Dosing With Food; Type: ACTIVE_COMPARATOR; Interventions: Drug: patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Group 1 - Dosing Without Food, Group 2 - Dosing With Food
C: Arm Label: Sodium Zirconium Cyclosilicate (SZC); Type: EXPERIMENTAL; Interventions: Drug: Sodium Zirconium Cyclosilicate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sodium Zirconium Cyclosilicate; Assigned to Arm(s): Sodium Zirconium Cyclosilicate (SZC) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Sodium Polystyrene Sulfonate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium polystyrene sulfonate | Arm Label: Lactose with carob gum; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactose with carob gum | Intervention Type: DRUG; Name: Sodium polystyrene sulfonate; Assigned to Arm(s): Sodium Polystyrene Sulfonate | Intervention Type: DRUG; Name: Lactose with carob gum; Assigned to Arm(s): Lactose with carob gum

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT)
Brief Summary: To compare the efficacy of Mitomycin C vs. Gemcitabine vs. no adjuvant treatment as a single intraoperative instillation in preventing recurrence of bladder cancer.


Options:
A: Arm Label: Cohort 1: Erdafitinib; Type: EXPERIMENTAL; Interventions: Drug: Erdafitinib | Arm Label: Cohort 1: Investigators Choice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Investigator Choice (Gemcitabine), Drug: Investigator Choice (Mitomycin C) | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: Erdafitinib | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: Erdafitinib | Intervention Type: DRUG; Name: Erdafitinib; Assigned to Arm(s): Cohort 1: Erdafitinib, Cohort 2, Cohort 3 | Intervention Type: DRUG; Name: Investigator Choice (Gemcitabine); Assigned to Arm(s): Cohort 1: Investigators Choice | Intervention Type: DRUG; Name: Investigator Choice (Mitomycin C); Assigned to Arm(s): Cohort 1: Investigators Choice
B: Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mitomycin C; Assigned to Arm(s): N/A
C: Arm Label: Mitomycin C; Type: EXPERIMENTAL; Interventions: Drug: Mitomycin C | Arm Label: Gemcitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Mitomycin C; Assigned to Arm(s): Mitomycin C | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rehabilitation Glasses for the Treatment of Hemispatial Neglect
Brief Summary: This project is designed to test a lightweight, portable, computerized pair of glasses that will help reduce some of the cognitive deficits seen in patients who have suffered damage to their right cerebral hemisphere.


Options:
A: Arm Label: Mirror therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mirror therapy | Arm Label: Sham mirror; Type: SHAM_COMPARATOR; Interventions: Behavioral: Sham mirror | Arm Label: Covered mirror; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Covered mirror | Intervention Type: BEHAVIORAL; Name: Mirror therapy; Assigned to Arm(s): Mirror therapy | Intervention Type: BEHAVIORAL; Name: Sham mirror; Assigned to Arm(s): Sham mirror | Intervention Type: BEHAVIORAL; Name: Covered mirror; Assigned to Arm(s): Covered mirror
B: Arm Label: Chronic; Type: EXPERIMENTAL; Interventions: Device: Computer rehabilitation glasses | Arm Label: Acute; Type: EXPERIMENTAL; Interventions: Device: Computer rehabilitation glasses | Arm Label: Optimization; Type: EXPERIMENTAL; Interventions: Device: Computer rehabilitation glasses | Arm Label: Duration; Type: ACTIVE_COMPARATOR; Interventions: Device: Computer rehabilitation glasses | Intervention Type: DEVICE; Name: Computer rehabilitation glasses; Assigned to Arm(s): Acute, Chronic, Duration, Optimization
C: Arm Label: Prism Adaptation Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Prism Adaptation Treatment | Arm Label: Control: Standard Rehabilitation Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Prism Adaptation Treatment; Assigned to Arm(s): Prism Adaptation Treatment
D: Arm Label: Optimization of OKS; Type: EXPERIMENTAL; Interventions: Device: OKS | Arm Label: Safety and efficacy study; Type: EXPERIMENTAL; Interventions: Device: OKS | Arm Label: Effect of repetitive stimulation; Type: EXPERIMENTAL; Interventions: Device: OKS | Arm Label: OKS and gait; Type: EXPERIMENTAL; Interventions: Device: OKS | Intervention Type: DEVICE; Name: OKS; Assigned to Arm(s): Effect of repetitive stimulation, OKS and gait, Optimization of OKS, Safety and efficacy study

Answer: B